Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Abstract
Background: Central pain in multiple sclerosis (MS) is common and often refractory to treatment.
Methods: We conducted a single-center, 5-week (1-week run-in, 4-week treatment), randomized, double-blind, placebo-controlled, parallel-group trial in 66 patients with MS and central pain states (59 dysesthetic, seven painful spasms) of a whole-plant cannabis-based medicine (CBM), containing delta-9-tetrahydrocannabinol:cannabidiol (THC:CBD) delivered via an oromucosal spray, as adjunctive analgesic treatment. Each spray delivered 2.7 mg of THC and 2.5 of CBD, and patients could gradually self-titrate to a maximum of 48 sprays in 24 hours.
Results: Sixty-four patients (97%) completed the trial, 34 received CBM. In week 4, the mean number of daily sprays taken of CBM (n = 32) was 9.6 (range 2 to 25, SD = 6.0) and of placebo (n = 31) was 19.1 (range 1 to 47, SD = 12.9). Pain and sleep disturbance were recorded daily on an 11-point numerical rating scale. CBM was superior to placebo in reducing the mean intensity of pain (CBM mean change −2.7, 95% CI: −3.4 to −2.0, placebo –1.4 95% CI: −2.0 to −0.8, comparison between groups, p = 0.005) and sleep disturbance (CBM mean change –2.5, 95% CI: −3.4 to −1.7, placebo –0.8, 95% CI: −1.5 to −0.1, comparison between groups, p = 0.003). CBM was generally well tolerated, although more patients on CBM than placebo reported dizziness, dry mouth, and somnolence. Cognitive side effects were limited to long-term memory storage.
Conclusions: Cannabis-based medicine is effective in reducing pain and sleep disturbance in patients with multiple sclerosis related central neuropathic pain and is mostly well tolerated.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
References
1.
Mersky H, Bogduk N. Classification of chronic pain. Seattle: IASP Press, 1994.
2.
Biovie J. Central pain. In: Wall, PD, Melzack R, eds. Textbook of pain, 4th ed. Hong Kong: Harcourt, 1999:879–914.
3.
Stenager E, Knudsen L, Jensen K. Acute and chronic pain syndromes in multiple sclerosis. Acta Neurol Scand 1991;84:197–200.
4.
Thompson AJ. Symptomatic treatment in multiple sclerosis. Curr Opin Neurol 1998;11:305–309.
5.
Bonica JJ. Introduction: semantic, epidemiologic, and educational issues. In: Casey, KL, eds. Pain and central nervous system disease: the central pain syndromes. New York: Raven Press, 1991:21.
6.
Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol 2001;63:569–611.
7.
Lyman WD, Sonett JR, Brosnan CF. Delta 9 tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 1989;23:73–81.
8.
Karst M, Salim K, Burstein CI, Hoy L, Schneider U. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain. A randomized controlled trial. JAMA 2003;290:1757–1762.
9.
Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole- plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17:21–29.
10.
Campbell FA, Tramer MR, Carroll D, Reynolds DJM, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323:13–16.
11.
Pertwee RG. Prescribing cannabinoids for multiple sclerosis: current issues. CNS Drugs 1999;11:327–334.
12.
Galer BS, Jensen MP. Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale. Neurology 1997;48:332–338.
13.
Rog DJ, Young CA. Validation and reliability of the Neuropathic Pain Scale in multiple sclerosis. Mult Scler 2001;7:S111 . Abstract.
14.
Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13:227–231.
15.
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability scale. Neurology 1983;33:1444–1452.
16.
Rao SM. Cognitive Function Study Group. National Multiple Sclerosis Society. A manual for the brief repeatable battery of neuropsychological tests in multiple sclerosis. New York: National Multiple Sclerosis Society, 1990.
17.
Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 1983;67:361–370.
18.
Sharrack B, Hughes RAC. Guy's Neurological Disability Scale (GNDS): a new disability measure for multiple sclerosis. Mult Scler 1999;5:223–233.
19.
Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia. JAMA 1998;280:1837–1842.
20.
Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus. JAMA 1998;280:1831–1836.
21.
Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004;329:253–258.
22.
Attal N, Bouhassira D. Can pain be more or less neuropathic? Pain 2004;110:510–511.
23.
Rasmussen PV, Sindrup SH, Jensen TS, Bach FW. Symptoms and signs in patients with suspected neuropathic pain. Pain 2004;110:461–469.
24.
Spissu A, Cannas A, Ferrigno P, Pelaghi AE, Spissu M. Anatomic correlates of painful tonic spasms in multiple sclerosis. Mov Disord 1999;14:331–335.
25.
Osterman PO, Westerberg CE. Paroxysmal attacks in multiple sclerosis. Brain 1975;98:189–202.
26.
Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in post-herpetic neuralgia: a randomized, placebo-controlled trial. Pain 2003;104:323–331.
27.
Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy. A randomized controlled trial. Neurology 2004;63:2104–2110.
28.
Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11- point numerical pain rating scale. Pain 2001;94:149–158.
29.
Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389–400.
30.
Houtchens MK, Richert JR, Sami A, Rose JW. Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler 1997;3:250–253.
31.
Ramsaransing G, Zwanikken C, De Keyser J. Drug points: worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ 2000;320:1113.
32.
Killestein J, Hoogervorst EL, Reif M, et al. Safety, tolerability and efficacy of orally administered cannabinoids in MS. Neurology 2002;58: 1404–1437.
33.
Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517–1526.
34.
Solowij N, Stephens RS, Roffmen RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA 2002;287:1123–1131.
35.
Langdon DW, Thompson AJ, Johnson KP, et al. The psychological effects of cannabis in MS: impact on cognition, pain, mood and fatigue. Mult Scler ECTRIMS 2003;9:S27 . Abstract.
Information & Authors
Information
Published In
Copyright
© 2005.
Publication History
Published online: September 26, 2005
Published in print: September 27, 2005
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Role of Cannabis in the Management of Chronic Non-Cancer Pain: A Narrative Review, Clinics and Practice, 15, 1, (16), (2025).https://doi.org/10.3390/clinpract15010016
- Phytocannabinoids—Evaluation of their therapeutic role in neuroinflammation, Exploration of Neuroprotective Therapy, (325-348), (2024).https://doi.org/10.37349/ent.2024.00087
- Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine, Pharmaceutics, 16, 2, (241), (2024).https://doi.org/10.3390/pharmaceutics16020241
- Evidence of Cannabidiol Effectiveness Associated or Not with Tetrahydrocannabinol in Topical Administration: A Scope Review, Pharmaceuticals, 17, 6, (748), (2024).https://doi.org/10.3390/ph17060748
- Cannabinoids—Multifunctional Compounds, Applications and Challenges—Mini Review, Molecules, 29, 20, (4923), (2024).https://doi.org/10.3390/molecules29204923
- Medicinal Plants for the Treatment of Neuropathic Pain: A Review of Randomized Controlled Trials, Current Pharmaceutical Biotechnology, 25, 5, (534-562), (2024).https://doi.org/10.2174/1389201024666230714143538
- The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex ® - A Cannabis-derived Spray , Mini-Reviews in Medicinal Chemistry, 24, 15, (1427-1448), (2024).https://doi.org/10.2174/0113895575285934240123110158
- Exploratory survey study on adjunctive use of medical cannabis for Gaucher disease, Rare Disease and Orphan Drugs Journal, 3, 3, (2024).https://doi.org/10.20517/rdodj.2024.17
- Emerging Therapeutic Modalities and Pharmacotherapies in Neuropathic Pain Management: A Systematic Review and Meta‐Analysis of Parallel Randomized Controlled Trials, Pain Research and Management, 2024, 1, (2024).https://doi.org/10.1155/prm/6782574
- Cannabis for medical use versus opioids for chronic non-cancer pain: a systematic review and network meta-analysis of randomised clinical trials, BMJ Open, 14, 1, (e068182), (2024).https://doi.org/10.1136/bmjopen-2022-068182
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.